Acción 6L7A BELLEROPHON THERAPEUTICS, INC.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Bellerophon Therapeutics, Inc. Börse Stuttgart

Acciones

6L7A

US0787713009

Diferido Börse Stuttgart
Otros sitios de cotización
 08:01:13 13/10/2023 		Varia. Cinco días. Varia. 1 de enero.
0,421 EUR +20,98 % Gráfico intradía de Bellerophon Therapeutics, Inc. +26,05 % -45,08 %
04/03 Bellerophon Therapeutics, Inc. Anuncia la dimisión de Mary Ann Cloyd y Scott Bruder como miembros del Consejo de Administración CI
2023 Bellerophon Therapeutics, Inc. anuncia cambios ejecutivos CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
North American Morning Briefing : Stock Futures -2-
North American Morning Briefing : More Tech -2-
North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge
North American Morning Briefing : Focus Turns to -2-
North American Morning Briefing : Stocks Set for -2-
Bellerophon Therapeutics, Inc. Announces Resignation of Mary Ann Cloyd and Scott Bruder as Members of Board of Directors
Bellerophon Therapeutics, Inc. Announces Executive Changes
Bellerophon Therapeutics, Inc. Announces Executive Changes
North American Morning Briefing : Stocks Futures Steady on Rates Optimism
Bellerophon Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Bellerophon Therapeutics, Inc.(NasdaqCM:BLPH) dropped from S&P TMI Index
Bellerophon Therapeutics Insider Sold Shares Worth $111,776, According to a Recent SEC Filing
Bellerophon Therapeutics, Inc. Announces Resignation of Theodore Wang as a Member of the Company's Board
Bellerophon Therapeutics, Inc.(OTCPK:BLPH) dropped from NASDAQ Composite Index
North American Morning Briefing : Focus Shifts to -2-
Bellerophon Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Investors Parse Inflation Data as Wall Street Set to Open Higher in Friday Trading
Bellerophon Therapeutics, Inc. Announces Resignation of Crispin Teufel as Board of Director
Bellerophon Therapeutics : Costs Associated with Exit/Disposal - Form 8-K
Bellerophon Therapeutics Announces Separation of Peter Fernandes as Chief Executive Officer, Effective July 15, 2023
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción BLPH
  4. Acción 6L7A
  5. Noticias Bellerophon Therapeutics, Inc.
  6. Otros idiomas